Lorenz Van der Linden1,2, Liesbeth Decoutere3, Karolien Walgraeve4, Koen Milisen5, Johan Flamaing6,7, Isabel Spriet4,8, Jos Tournoy6,7. 1. Pharmacy Department, University Hospitals Leuven, Herestraat 49, 3000, Louvain, Belgium. lorenz.vanderlinden@uzleuven.be. 2. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Louvain, Belgium. lorenz.vanderlinden@uzleuven.be. 3. Pharmacy Department, Jessa Hospital, Hasselt, Belgium. 4. Pharmacy Department, University Hospitals Leuven, Herestraat 49, 3000, Louvain, Belgium. 5. Department of Public Health and Primary Care, Health Services and Nursing Research, KU Leuven, Louvain, Belgium. 6. Department of Geriatric Medicine, University Hospitals Leuven, Louvain, Belgium. 7. Department of Clinical and Experimental Medicine, KU Leuven, Louvain, Belgium. 8. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Louvain, Belgium.
Abstract
BACKGROUND: Polypharmacy and potentially inappropriate drugs have been associated with negative outcomes in older adults which might be reduced by pharmacist interventions. OBJECTIVES: Our objective was to evaluate the effect of a pharmacist intervention, consisting of the application of the Rationalization of home medication by an Adjusted STOPP in older Patients (RASP) list and a pharmacist-led medication review on polypharmacy, the quality of prescribing, and clinical outcome in geriatric inpatients. METHODS: A monocentric, prospective controlled trial was undertaken at the geriatric wards of a large university hospital. Pharmacists applied the RASP list to the drugs reconciled on admission and additionally performed an expert-based medication review, upon which recommendations were provided to the treating physicians. The primary outcome was the composite endpoint of drug discontinuation and dose reduction of drugs taken on admission. Secondary outcomes included RASP-identified potentially inappropriate medications (PIMs), the number of Emergency Department (ED) visits and quality of life (QOL) registered up to 3 months after discharge. RESULTS: On average, patients (n = 172) took 10 drugs on admission and were 84.5 years (standard deviation 4.8) of age. More drugs were discontinued or reduced in dose in the intervention group {control vs.intervention:median (interquartile range [IQR]) 3 (2-5) vs. 5 (3-7); p < 0.001}. More PIMs were discontinued in the intervention group, leading to less PIM at discharge [control vs.intervention:median (IQR) 2 (1-3) vs. 0.5 (0-1); p < 0.001]. No signal of harm was seen, and a significant improvement of QOL and less ED visits without hospitalization were observed. CONCLUSIONS: The combined intervention safely reduced drug use in very old inpatients and outperformed usual geriatric care. An increased QOL was seen, as well as a trend towards less ED visits. ClinicalTrials.gov Identifier: NCT01513265.
RCT Entities:
BACKGROUND: Polypharmacy and potentially inappropriate drugs have been associated with negative outcomes in older adults which might be reduced by pharmacist interventions. OBJECTIVES: Our objective was to evaluate the effect of a pharmacist intervention, consisting of the application of the Rationalization of home medication by an Adjusted STOPP in older Patients (RASP) list and a pharmacist-led medication review on polypharmacy, the quality of prescribing, and clinical outcome in geriatric inpatients. METHODS: A monocentric, prospective controlled trial was undertaken at the geriatric wards of a large university hospital. Pharmacists applied the RASP list to the drugs reconciled on admission and additionally performed an expert-based medication review, upon which recommendations were provided to the treating physicians. The primary outcome was the composite endpoint of drug discontinuation and dose reduction of drugs taken on admission. Secondary outcomes included RASP-identified potentially inappropriate medications (PIMs), the number of Emergency Department (ED) visits and quality of life (QOL) registered up to 3 months after discharge. RESULTS: On average, patients (n = 172) took 10 drugs on admission and were 84.5 years (standard deviation 4.8) of age. More drugs were discontinued or reduced in dose in the intervention group {control vs.intervention:median (interquartile range [IQR]) 3 (2-5) vs. 5 (3-7); p < 0.001}. More PIMs were discontinued in the intervention group, leading to less PIM at discharge [control vs.intervention:median (IQR) 2 (1-3) vs. 0.5 (0-1); p < 0.001]. No signal of harm was seen, and a significant improvement of QOL and less ED visits without hospitalization were observed. CONCLUSIONS: The combined intervention safely reduced drug use in very old inpatients and outperformed usual geriatric care. An increased QOL was seen, as well as a trend towards less ED visits. ClinicalTrials.gov Identifier: NCT01513265.
Authors: G P Samsa; J T Hanlon; K E Schmader; M Weinberger; E C Clipp; K M Uttech; I K Lewis; P B Landsman; H J Cohen Journal: J Clin Epidemiol Date: 1994-08 Impact factor: 6.437
Authors: J T Hanlon; M Weinberger; G P Samsa; K E Schmader; K M Uttech; I K Lewis; P A Cowper; P B Landsman; H J Cohen; J R Feussner Journal: Am J Med Date: 1996-04 Impact factor: 4.965
Authors: Michiel C Meulendijk; Marco R Spruit; A Clara Drenth-van Maanen; Mattijs E Numans; Sjaak Brinkkemper; Paul A F Jansen; Wilma Knol Journal: Drugs Aging Date: 2015-06 Impact factor: 3.923
Authors: Jennifer A Pruskowski; Sydney Springer; Carolyn T Thorpe; Michele Klein-Fedyshin; Steven M Handler Journal: Drugs Aging Date: 2019-12 Impact factor: 3.923
Authors: E Delgado-Silveira; M Vélez-Díaz-Pallarés; M Muñoz-García; A Correa-Pérez; A M Álvarez-Díaz; A J Cruz-Jentoft Journal: Eur Geriatr Med Date: 2021-05-07 Impact factor: 1.710
Authors: Hannah De Schutter; Julie Hias; Laura Hellemans; Karolien Walgraeve; Jos Tournoy; Peter Verhamme; Peter Sinnaeve; Rik Willems; Walter Droogné; Christophe Vandenbriele; Lucas Van Aelst; Thomas Vanassche; Lorenz Van der Linden Journal: Eur Geriatr Med Date: 2022-10-14 Impact factor: 3.269
Authors: Lorenz Roger Van der Linden; Julie Hias; Karolien Walgraeve; Johan Flamaing; Isabel Isabel Spriet; Jos Tournoy Journal: Eur J Hosp Pharm Date: 2019-08-24
Authors: Lauren Dautzenberg; Lisa Bretagne; Huiberdina L Koek; Sofia Tsokani; Stella Zevgiti; Nicolas Rodondi; Rob J P M Scholten; Anne W Rutjes; Marcello Di Nisio; Renee C M A Raijmann; Marielle Emmelot-Vonk; Emma L M Jennings; Olivia Dalleur; Dimitris Mavridis; Wilma Knol Journal: J Am Geriatr Soc Date: 2021-02-12 Impact factor: 5.562
Authors: Audrey Rankin; Cathal A Cadogan; Susan M Patterson; Ngaire Kerse; Chris R Cardwell; Marie C Bradley; Cristin Ryan; Carmel Hughes Journal: Cochrane Database Syst Rev Date: 2018-09-03